The ophthalmology market values innovation approaches, demonstrated by premiums paid for acquisition of first-in-class therapies and public market support of ophthalmology gene therapy companies.
Market Insight: Echoe Bouta, PhD, Scott Terchiak, and Oded Ben-Joseph, PhD, MBA
The ophthalmology market values innovative approaches, demonstrated by premiums paid for acquisition of first-in-class therapies and public market support of ophthalmology gene therapy companies.
Total economic burden of vision loss and eye disorders surpasses $130 billion in the U.S., a figure expected to rise due to the aging population. We examined recent ophthalmology market dynamics between 2015 and 2018, including industry-sponsored clinical trials, financing events, mergers and acquisition transactions and initial public offerings. These dynamics are utilized to assess the overall activity of the sector and interest by venture capitalists, strategic players and the public market.
Appointment of Charles Simmons as Managing Director continues to strengthen Outcome’s capabilities
Read MoreOutcome Capital Life Science Market Pulse October 2024 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?